HK1079203A1 - Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders - Google Patents
Substituted amine derivatives and methods of use in the treatment of angiogenesis related disordersInfo
- Publication number
- HK1079203A1 HK1079203A1 HK05111248A HK05111248A HK1079203A1 HK 1079203 A1 HK1079203 A1 HK 1079203A1 HK 05111248 A HK05111248 A HK 05111248A HK 05111248 A HK05111248 A HK 05111248A HK 1079203 A1 HK1079203 A1 HK 1079203A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- methods
- related disorders
- substituted amine
- amine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/197,918 US7102009B2 (en) | 2001-01-12 | 2002-07-17 | Substituted amine derivatives and methods of use |
PCT/US2003/022275 WO2004007481A2 (en) | 2002-07-17 | 2003-07-15 | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1079203A1 true HK1079203A1 (en) | 2006-03-31 |
Family
ID=30115143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05111248A HK1079203A1 (en) | 2002-07-17 | 2005-12-08 | Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders |
Country Status (14)
Country | Link |
---|---|
US (1) | US7102009B2 (xx) |
EP (1) | EP1562933B1 (xx) |
JP (1) | JP4392348B2 (xx) |
AR (1) | AR040595A1 (xx) |
AT (1) | ATE389649T1 (xx) |
AU (1) | AU2003263784B2 (xx) |
CA (1) | CA2492045A1 (xx) |
DE (1) | DE60319865T2 (xx) |
ES (1) | ES2302946T3 (xx) |
HK (1) | HK1079203A1 (xx) |
MX (1) | MXPA05000659A (xx) |
PL (1) | PL377861A1 (xx) |
TW (1) | TW200405811A (xx) |
WO (1) | WO2004007481A2 (xx) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
PL233177B1 (pl) | 2002-03-13 | 2019-09-30 | Array Biopharma Inc | (2-hydroksyetoksy)amid kwasu 6-(4-bromo-2-chlorofenyloamino)- 7-fluoro-3-metylo-3H-benzimidazolo-5-karboksylowego, zawierająca ten związek kompozycja farmaceutyczna oraz ich zastosowanie |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
MXPA05009459A (es) * | 2003-03-03 | 2006-05-17 | Array Biopharma Inc | Inhibidores de p38 y sus metodos de uso. |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
JP5105874B2 (ja) | 2003-07-18 | 2012-12-26 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合因子 |
TWI350168B (en) * | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
JP2008504279A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
JP2008504275A (ja) | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | N−置換ピペリジンおよびその医薬としての使用 |
US7687665B2 (en) * | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
NZ551602A (en) * | 2004-06-24 | 2010-11-26 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
PL1773768T3 (pl) * | 2004-07-30 | 2019-03-29 | Exelixis, Inc. | Pochodne pirolu jako środki farmaceutyczne |
BRPI0514230A (pt) * | 2004-08-10 | 2008-06-03 | Incyte Corp | compostos de amido e seu uso como produtos farmacêuticos |
JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
GB0611907D0 (en) * | 2006-06-15 | 2006-07-26 | Glaxo Group Ltd | Compounds |
EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
CN101133027B (zh) * | 2005-03-04 | 2011-03-30 | 弗·哈夫曼-拉罗切有限公司 | 作为mglur5拮抗剂的吡啶-2-甲酰胺衍生物 |
JP2006290883A (ja) * | 2005-03-17 | 2006-10-26 | Nippon Nohyaku Co Ltd | 置換ヘテロ環カルボン酸アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法 |
EP1894919B1 (en) * | 2005-06-07 | 2012-03-28 | Shionogi & Co., Ltd. | Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity |
BRPI0613987A2 (pt) | 2005-07-26 | 2011-03-01 | Glaxo Group Ltd | derivados de benzilpiperazina e seu uso médico |
US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
GB0524814D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
JP5131990B2 (ja) * | 2006-01-31 | 2013-01-30 | アレイ バイオファーマ、インコーポレイテッド | キナーゼ阻害剤およびその使用方法 |
EP1987023B1 (en) | 2006-02-10 | 2010-11-24 | Amgen, Inc | Hydrate forms of amg706 |
US20070213311A1 (en) * | 2006-03-02 | 2007-09-13 | Yun-Long Li | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
US7700599B2 (en) * | 2006-06-28 | 2010-04-20 | Glaxo Group Limited | Gpr38 Receptor Agonists |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
CA2673652A1 (en) | 2007-01-09 | 2008-07-17 | Amgen Inc. | Bis-aryl amide derivatives and methods of use |
US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
JP5374377B2 (ja) | 2007-10-18 | 2013-12-25 | 武田薬品工業株式会社 | 複素環化合物 |
AU2009308483C1 (en) * | 2008-10-22 | 2014-01-23 | Acucela, Inc. | Compounds for treating ophthalmic diseases and disorders |
JO3067B1 (ar) | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
US8853215B2 (en) | 2009-04-16 | 2014-10-07 | Takeda Pharmaceutical Company Limited | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes |
US8470820B2 (en) * | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
UA112769C2 (uk) | 2011-02-18 | 2016-10-25 | Ендо Фармасьютікалз Інк. | Аміноінданові сполуки і їх застосування при лікуванні болю |
SG193580A1 (en) | 2011-03-23 | 2013-10-30 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
JP2014517847A (ja) * | 2011-05-24 | 2014-07-24 | ザ ウィスター インスティテュート | エプスタイン・バー核抗原1の活性を調節する組成物および方法 |
WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
TWI603957B (zh) | 2012-08-15 | 2017-11-01 | 阿沙納生物科學有限責任公司 | 胺基氫茚化合物用於治療膀胱過動症及間質性膀胱炎之用途 |
WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
CN103012428A (zh) | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
WO2014118186A1 (en) * | 2013-01-30 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
WO2016112111A1 (en) | 2015-01-08 | 2016-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
JP6800872B2 (ja) | 2015-03-06 | 2020-12-16 | ファーマケア,インク. | リシルオキシダーゼ様2阻害剤とその使用 |
EP3795568A1 (en) | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
US10774069B2 (en) | 2016-09-07 | 2020-09-15 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
EP4052707A1 (en) | 2016-09-07 | 2022-09-07 | Pharmakea, Inc. | Uses of a lysyl oxidase-like 2 inhibitor |
SG10201913491PA (en) | 2016-12-22 | 2020-03-30 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
MA50077A (fr) | 2017-09-08 | 2020-07-15 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2019213526A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7266043B2 (ja) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
CA3099045A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
MX2020012731A (es) | 2018-06-01 | 2021-02-22 | Amgen Inc | Inhibidores de kras g12c y metodos para su uso. |
US20190375749A1 (en) | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
WO2020050890A2 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
EP3897855B1 (en) | 2018-12-20 | 2023-06-07 | Amgen Inc. | Kif18a inhibitors |
EP3898616A1 (en) | 2018-12-20 | 2021-10-27 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
CA3123044A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
PE20211475A1 (es) | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
MX2021010323A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
US11236091B2 (en) | 2019-05-21 | 2022-02-01 | Amgen Inc. | Solid state forms |
JP2022540200A (ja) | 2019-07-11 | 2022-09-14 | エスケイプ・バイオ・インコーポレイテッド | Lrrk2阻害剤としてのインダゾールおよびアザインダゾール |
WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
CA3147276A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
JP2022542319A (ja) | 2019-08-02 | 2022-09-30 | アムジエン・インコーポレーテツド | Kif18a阻害剤 |
CN114269731A (zh) | 2019-08-02 | 2022-04-01 | 美国安进公司 | Kif18a抑制剂 |
JP2022552873A (ja) | 2019-10-24 | 2022-12-20 | アムジエン・インコーポレーテツド | がんの治療におけるkras g12c及びkras g12d阻害剤として有用なピリドピリミジン誘導体 |
CN114901366A (zh) | 2019-11-04 | 2022-08-12 | 锐新医药公司 | Ras抑制剂 |
CR20220241A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
KR20220101125A (ko) | 2019-11-14 | 2022-07-19 | 암젠 인크 | Kras g12c 억제제 화합물의 개선된 합성 |
WO2021097207A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
KR20220124768A (ko) | 2020-01-07 | 2022-09-14 | 레볼루션 메디슨즈, 인크. | Shp2 억제제 투여 및 암 치료방법 |
CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
MX2023013084A (es) | 2021-05-05 | 2023-11-17 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer. |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
IL308193A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors |
IL309666A (en) | 2021-07-09 | 2024-02-01 | Plexium Inc | Aryl compounds and pharmaceutical preparations that modulate IKZF2 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
WO2024143336A1 (ja) * | 2022-12-28 | 2024-07-04 | 日本曹達株式会社 | ヒドラジド化合物および農園芸用殺菌剤 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH438343A (de) | 1962-11-08 | 1967-06-30 | Thomae Gmbh Dr K | Verfahren zur Herstellung von 5,6-Dihydro-6-oxo-11H-pyrido (2,3-b) (1,4)-benzodiazepinen |
US3226394A (en) * | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
US3822277A (en) | 1967-11-13 | 1974-07-02 | C Dufour | Certain pyridyl cyclopropylamides |
BE794226A (fr) | 1972-01-21 | 1973-07-18 | Synthelabo | Derives de la quinoleine, leur preparation et les medicaments qui en contiennent |
DE2934543A1 (de) | 1979-08-27 | 1981-04-02 | Basf Ag, 6700 Ludwigshafen | Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
DE3305755A1 (de) | 1983-02-19 | 1984-08-23 | Gödecke AG, 1000 Berlin | N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems |
EP0393529B1 (en) | 1989-04-20 | 1993-06-30 | Boehringer Ingelheim Pharmaceuticals Inc. | 5,11-dihydro-6H-dipyrido [3,2-b:2',3'-e][1,4]diazepin-6-ones and their use in the prevention or treatment of AIDS |
DK0410148T3 (da) | 1989-06-28 | 1994-08-08 | Boehringer Ingelheim Pharma | Hidtil ukendte 5,11-dihydro-6H-dipyrido(3,2-b:2,3-e)-(1,4)diazepin-6-oner og -thioner og deres anvendelse til forebyggelse eller behandling af AIDS |
CA2030056C (en) | 1989-11-17 | 1995-10-17 | Karl D. Hargrave | 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection |
US5571912A (en) | 1990-10-19 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines |
EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
US5559135A (en) | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
US5532358A (en) * | 1994-10-12 | 1996-07-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones |
TW321649B (xx) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5663357A (en) | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
US6008234A (en) | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
AUPO395396A0 (en) | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
US6380218B1 (en) | 1997-04-04 | 2002-04-30 | Pfizer Inc | Nicotinamide derivatives |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
AU8269398A (en) | 1997-06-26 | 1999-01-19 | Eli Lilly And Company | Antithrombotic agents |
WO1999000121A1 (en) | 1997-06-26 | 1999-01-07 | Eli Lilly And Company | Antithrombotic agents |
EP1019045B1 (en) | 1997-06-26 | 2005-06-08 | Eli Lilly And Company | Antithrombotic agents |
IL133625A0 (en) | 1997-06-26 | 2001-04-30 | Lilly Co Eli | Antithrombotic agents |
US6140351A (en) * | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
AU751856B2 (en) | 1997-12-19 | 2002-08-29 | Schering Aktiengesellschaft | Ortho-anthranilamide derivatives as anti-coagulants |
US6271237B1 (en) | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
JP2002516909A (ja) | 1998-06-05 | 2002-06-11 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換1−(4−アミノフェニル)ピラゾール及び抗炎症剤としてのそれらの使用 |
EP1614678B1 (en) | 1998-07-08 | 2014-01-01 | Sanofi-Aventis Deutschland GmbH | Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
ATE326453T1 (de) | 1998-12-23 | 2006-06-15 | Lilly Co Eli | Antithrombotische amide |
EP1140903B1 (en) | 1998-12-23 | 2004-08-04 | Eli Lilly And Company | Aromatic amides |
AU2364600A (en) | 1998-12-23 | 2000-07-31 | Eli Lilly And Company | Heteroroaromatic amides as inhibitor of factor xa |
ID30552A (id) | 1999-02-10 | 2001-12-20 | Astrazeneca Ab | Turunan kuinazolina sebagai penghambat angiogenesis |
JP2000256358A (ja) | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
DK1169038T3 (da) | 1999-04-15 | 2012-11-26 | Bristol Myers Squibb Co | Cykliske proteintyrosinkinaseinhibitorer |
HN2000000051A (es) | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
AUPQ365299A0 (en) | 1999-10-25 | 1999-11-18 | Fujisawa Pharmaceutical Co., Ltd. | Anthranilic acid derivatives |
GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
WO2001055115A1 (en) | 2000-01-27 | 2001-08-02 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2001078648A2 (en) * | 2000-04-17 | 2001-10-25 | Dong Wha Pharm. Ind. Co., Ltd. | 6-methylnicotinamide derivatives as antiviral agents |
DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
DE10023492A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
DE10023484A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
DE10023485A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel |
DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
DE10060809A1 (de) | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002076959A1 (fr) | 2001-03-23 | 2002-10-03 | Takeda Chemical Industries, Ltd. | Derive heterocyclique a cinq membres d'acide alcanoique |
US7312235B2 (en) | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
BR0209485A (pt) | 2001-05-08 | 2004-07-06 | Schering Ag | Antranilamidapiridinamidas seletivas como inibidores vegfr-2 e vegfr-3 |
JP2004528378A (ja) | 2001-05-08 | 2004-09-16 | シエーリング アクチエンゲゼルシャフト | N−オキシドアントラニルアミド誘導体と医薬製剤としての利用 |
GB0203193D0 (en) | 2002-02-11 | 2002-03-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
ES2292988T3 (es) | 2002-02-11 | 2008-03-16 | Pfizer Inc. | Derivados de nicotinamida utiles como inhibidores de pde4. |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
US7517894B2 (en) | 2002-07-31 | 2009-04-14 | Bayer Schering Pharma Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
-
2002
- 2002-07-17 US US10/197,918 patent/US7102009B2/en not_active Expired - Fee Related
-
2003
- 2003-07-15 AU AU2003263784A patent/AU2003263784B2/en not_active Ceased
- 2003-07-15 MX MXPA05000659A patent/MXPA05000659A/es active IP Right Grant
- 2003-07-15 WO PCT/US2003/022275 patent/WO2004007481A2/en active IP Right Grant
- 2003-07-15 AT AT03764755T patent/ATE389649T1/de not_active IP Right Cessation
- 2003-07-15 JP JP2004521922A patent/JP4392348B2/ja not_active Expired - Fee Related
- 2003-07-15 EP EP03764755A patent/EP1562933B1/en not_active Expired - Lifetime
- 2003-07-15 PL PL377861A patent/PL377861A1/pl not_active Application Discontinuation
- 2003-07-15 ES ES03764755T patent/ES2302946T3/es not_active Expired - Lifetime
- 2003-07-15 CA CA002492045A patent/CA2492045A1/en not_active Abandoned
- 2003-07-15 DE DE60319865T patent/DE60319865T2/de not_active Expired - Lifetime
- 2003-07-17 TW TW092119541A patent/TW200405811A/zh unknown
- 2003-07-17 AR AR20030102568A patent/AR040595A1/es unknown
-
2005
- 2005-12-08 HK HK05111248A patent/HK1079203A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2003263784A1 (en) | 2004-02-02 |
US20030203922A1 (en) | 2003-10-30 |
TW200405811A (en) | 2004-04-16 |
EP1562933B1 (en) | 2008-03-19 |
DE60319865D1 (de) | 2008-04-30 |
WO2004007481A2 (en) | 2004-01-22 |
EP1562933A2 (en) | 2005-08-17 |
MXPA05000659A (es) | 2005-03-31 |
ES2302946T3 (es) | 2008-08-01 |
AR040595A1 (es) | 2005-04-13 |
CA2492045A1 (en) | 2004-01-22 |
AU2003263784B2 (en) | 2007-07-19 |
JP4392348B2 (ja) | 2009-12-24 |
DE60319865T2 (de) | 2009-03-05 |
US7102009B2 (en) | 2006-09-05 |
WO2004007481A3 (en) | 2004-02-19 |
JP2006502118A (ja) | 2006-01-19 |
PL377861A1 (pl) | 2006-02-20 |
ATE389649T1 (de) | 2008-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1079203A1 (en) | Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders | |
HK1089155A1 (en) | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | |
HUP0302719A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
EP1509279A4 (en) | DEVICE AND METHOD FOR THE TREATMENT OF HEART DISEASES | |
IL174734A0 (en) | Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders | |
AU2003233583A8 (en) | Oral lactoferrin in the treatment of respiratory disorders | |
AU2003286567A8 (en) | Methods for the treatment of skin disorders | |
EP1465615A4 (en) | TRICYCLIC BISENONE DERIVATIVES AND METHODS OF USE | |
HK1109867A1 (en) | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | |
PL374700A1 (en) | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders | |
IL163102A (en) | Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders | |
ME01219B (me) | Alfa-aminoamid derivati korisni u liječenju bolesti zavisnosti | |
ZA200410409B (en) | Use of thio-oxindole derivatives in treatment of hormonerelated conditions | |
EP1515725A4 (en) | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED ILLNESSES | |
ZA200410401B (en) | Use of thio-oxindole derivatives in treatment of skin disorders | |
NO20032636D0 (no) | 3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser | |
IL183656A0 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
HK1203216A1 (en) | Materials and methods for treating disorders of the ear | |
NO20031903L (no) | Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser | |
IL165216A0 (en) | Methods of treating gastrointestinal and genitouririnary pain disorders using vinlafaxin and derivatives | |
EP1478438A4 (en) | TECHNIQUES AND COMPOSITIONS FOR THE TREATMENT OF ASTHMA AND RELATED DISORDERS | |
IL157145A0 (en) | Use of dc23 antagonists for the treatment of neoplastic disorders | |
PL376894A1 (pl) | Pochodne 4-(fenylopiperazynylometylo) benzamidu i ich zastosowanie do leczenia bólu lub zaburzeń żołądkowo-jelitowych | |
PL370746A1 (en) | Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma | |
PL376895A1 (pl) | Pochodne 4-(fenylopiperazynylometylo) benzamidu i ich zastosowanie do leczenia bólu lub zaburzeń żołądkowo-jelitowych |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20120715 |